ArticleNPJ precision oncology2026
Deep learning based individualized cross-platform molecular subtype classification of B-lineage acute lymphoblastic leukemia.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Molecular subtypes of B-cell acute lymphoblastic leukemia (B-ALL) are essential in modern clinical treatment. However, the fast emerging subtypes and the requirement of complex multi-omic diagnostics are continuously challenging the clinical subtypes classification in sensitivity, cost, and turnaround time. We develop B-cell Acute Lymphoblastic Leukemia Subtype Identification based on gene eXpression (BALL6), a robust deep learning framework for cross-platform B-ALL subtyping. BALL6 utilizes a recurrent neural network trained on rank-transformed expression values of feature genes, capturing subtype signals while inherently minimizing technical noise. We implement in BALL6 the rank-based augmentation framework which further enhances its performance on data-limited or imbalanced datasets. BALL6 includes two integrated models: an AL model distinguishing B-ALL, T-ALL, and AML, and a B-ALL model identifying the most updated 20 established molecular subtypes. BALL6 demonstrates robust accuracy across multiple independent datasets, achieving 99.38% (AL model) and 93.84% (B-ALL model) accuracy on previously unseen data. Notably, BALL6 is robust to missing values, which enables its cross-platform application. This is demonstrated through reliable subtype prediction by BALL6 with sparse gene expression profiles from scRNA-seq data. BALL6 is open-sourced with an accessible web tool ( https://cccg.ronglian.com/#/analysis ), facilitating its broad applications in leukemia research and clinical diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.